Our vision is to increase the efficacy of translation of its world class fundamental research, and its impact upon clinical practice and patient wellbeing.
Professor Mark Wills
Our vision is to increase the efficacy of translation of its world class fundamental research, and its impact upon clinical practice and patient wellbeing.
Professor Mark Wills
11 April 2025
Professor Stefan Marciniak and colleagues at the University of Cambridge has identified the link between the gene in question, FLCN, and a condition known as Birt-Hogg-Dubé syndrome, symptoms of which include benign skin tumours, lung cysts, and an increased risk of kidney cancer.
Combining antibiotics to tackle antimicrobial resistance
27 March 2025
William Hope (University of Liverpool), our professor Sharon Peacock and colleagues have published a new comment on Nature Microbiology, suggesting combining antibiotics remains a promising approach to treat patients and to prevent the emergence of antimicrobial resistance.
Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing
18 March 2025
Maxion Therapeutics, a Cambridge-based biotechnology company co-founded by Dr. John McCafferty, Associate Professor at CITIID and the Department of Medicine, University of Cambridge, has successfully raised $72 million in an oversubscribed Series A financing round. The company is developing antibody-based KnotBody® drugs...
© 2025 University of Cambridge
